| 1 | Exploring novel inflammation-related genetic and hematological predictors of response to |
|----|---|
| 2 | neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
| 3 | Mladen Marinkovic ¹ , Suzana Stojanovic-Rundic ^{1,2} , Aleksandra Stanojevic ³ , Marija Ostojic ³ , |
| 4 | Dusica Gavrilovic ⁴ , Radmila Jankovic ³ , Natasa Maksimovic ⁵ , Rafael Stroggilos ⁶ , Jerome |
| 5 | Zoidakis ^{6,7} , Sergi Castellví-Bel ⁸ , Remond J.A. Fijneman ⁹ , Milena Cavic ^{3*} |
| 6 | |
| 7 | ¹ Clinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for |
| 8 | Oncology and Radiology of Serbia, Belgrade, Serbia |
| 9 | ² Faculty of Medicine, University of Belgrade, Belgrade, Serbia |
| 10 | ³ Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, |
| 11 | Belgrade, Serbia |
| 12 | ⁴ Data Center, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia |
| 13 | ⁵ Institute of Epidemiology, University of Belgrade, Belgrade, Serbia |
| 14 | ⁶ Department of Biotechnology, Biomedical Research Foundation, Academy of Athens, Athens, |
| 15 | Greece |
| 16 | ⁷ Department of Biology, National and Kapodistrian University of Athens, Athens, Greece |
| 17 | ⁸ Gastroenterology Department, Fundació Recerca Clínic Barcelona-Institut d'Investigacions |
| 18 | Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades |
| 19 | Hepáticas y Digestivas, Clínic Barcelona, University of Barcelona, Barcelona, Spain |
| 20 | ⁹ Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands |
| 21 | |
| 22 | *Corresponding author: |
| 23 | Dr Milena Cavic |
| 24 | Institute for Oncology and Radiology of Serbia |
| 25 | Department of Experimental Oncology |
| 26 | Pasterova 14, 11000 Belgrade, Serbia |
| 27 | Phone number: + 381 11 2067210 |
| 28 | Fax number: + 381 11 2067294 |
| | |

29 E-mail: milena.cavic@ncrc.ac.rs

30 Abstract

Background: The standard initial treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). In order to select patients who would benefit the most from nCRT, there is a strong need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammation-related genetic, and hematological parameters in the prediction of response after nCRT.

Methods: In silico analysis of published transcriptomics datasets was conducted to identify 36 the best candidate genes, whose expression will be measured using quantitative Real Time PCR 37 (qRT-PCR) in pretreatment formaline-fixed paraffin-embedded (FFPE) samples. In this study, 75 38 patients with LARC, between June 2020 and January 2022, were prospectively included. Patients 39 were assessed for tumor response in the 8th week after nCRT completion with pelvic MRI scan and 40 rigid proctoscopy. For patients with a clinical complete response (cCR) and initially distant located 41 tumor no immediate surgery was suggested ("watch and wait" approach). The response after surgery 42 was assessed using histopathological tumor regression grading (TRG) categories from postoperative 43 specimens by Mandard. Responders (R) were defined as patients with cCR without operative 44 45 treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-responders (NR) were 46 patients classified as TRG 3-5.

Results: Responders group comprised 35 patients (46.6%) and NR group included 53.4% 47 48 of patients. Analysis of published transcriptomics data identified genes that could predict response to treatment and their significance was assessed in our cohort by qRT-PCR. When comparison was 49 made in the subgroup of patients who were operated (TRG1 vs. TRG4), the expression of IDO1 was 50 significantly deregulated (p < 0.05). Among hematological parameters between R and NR a 51 significant difference in the response was detected for neutrophil-to-monocyte ratio (NMR), initial 52 basophil, eosinophil and monocyte counts (p < 0.01). According to MRI findings, non-responders 53 were more often presented with extramural vascular invasion (p < 0.05). 54

55 **Conclusion:** Based on logistic regression model, factors associated with favorable response 56 to nCRT were found to be tumor morphology as well as hematological parameters which can be 57 easily and routinely derived from initial laboratory results (NMR, eosinophil, basophil and 58 monocyte counts) in a minimally invasive manner. Using various metrics, an aggregated score of 59 the initial eosinophil, basophil, and monocyte counts demonstrated the best predictive performance.

Keywords: inflammation, locally advanced rectal cancer, neoadjuvant chemoradiotherapy,predictive biomarkers.

62 Introduction

63 In 2020, colorectal cancer (CRC) was the third most common malignant disease with 1.9 million new cases worldwide ¹. With 0.9 million deaths, it held the second place of cancer-related mortality 64 causes in 2020¹. In Serbia, in 2020, there were 2,956 new cases and a total of 1,493 deaths related 65 to rectal cancer, which placed Serbia in the group of countries with a high incidence and mortality 66 rate for this disease ¹. In the majority of cases, it is diagnosed in advanced stages, when treatment 67 options are limited. In this regard, in the past we have profiled the diagnostic, prognostic and 68 predictive factors for cancers of the digestive system, leading to improved research strategies for 69 patient management and care ^{2–7}. However, there is a need for better primary prevention, more 70 effective screening program, diagnosis at an earlier stage of the disease and improvement of existing 71 treatment modalities in our country and on a global level. 72

The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant 73 74 chemoradiotherapy (nCRT) followed by total mesorectal excision with or without adjuvant chemotherapy. The pathologic complete response (pCR) after nCRT is achieved in 10-30% of cases 75 ⁸. It has been reported that pCR, independent of the initial clinical T and N stage of the disease, was 76 77 associated with better local and distant disease control, as well as longer disease-free and overall survival⁹. Other reports showed that radical surgical treatment was related to significant morbidity, 78 including postoperative complications ¹⁰. Further investigations were directed towards less invasive 79 surgical treatment or avoiding surgery ("watch and wait" approach) in patients with favorable 80 response to nCRT, in order to improve the quality of life. Since 2004, a group of researchers led by 81 82 Angelita Habr-Gama have contributed greatly in this area by pointing out the effectiveness and safety of this approach ¹¹. The current management of LARC uses the clinical complete response 83 (cCR) as the point of reference for identifying patients for whom a non-operative approach may be 84 a viable option ¹². However, the clinical response poorly correlates with the pathologic response ¹³. 85

Other research trends in this field were dedicated to prolonging the period between completion of 86 neoadjuvant treatment and surgery, changing the type and regimen of chemotherapy, as well as 87 increasing the radiotherapy doses. These approaches aimed to achieve a higher percentage of good 88 response to the initial treatment. As not all patients will benefit from these treatment modifications, 89 there is a need to categorize them initially before treatment. In order to select patients who would 90 91 benefit the most from a neoadjuvant treatment, there is a strong demand to discover and characterize predictive biomarkers. Despite numerous studies in this field, until now no molecular marker has 92 been implemented as a diagnostic or predictive parameter in routine clinical practice of LARC. This 93 is stressed by the fact that there was not enough matching regarding results of published studies in 94 this area and only two genes (MMP4 and FLNA) were shown to be significant in more than one 95 study ¹⁴. Limitations of previous studies included a small number of patients, the absence of 96 reproducibility of measurements, the use of different methodologies, the retrospective nature of the 97

98 studies, the heterogeneity of the studied groups and applied treatment modalities, as well as the lack 99 of verification of the findings. Further research was aimed at examining the cumulative effect of 100 molecular markers in combination with radiological and clinical data. An example of such 101 successful research is the examination of the correlation between the expression of three protein 102 molecular markers (c-MYC, PCNA and TIMP1) and magnetic resonance imaging (MRI) 103 parameters ¹⁵.

The association between inflammatory bowel disease and the higher risk of developing colorectal cancer is well known ^{16,17}. Also, there is evidence of the role of inflammation in sporadic colorectal cancer ^{18,19}. Chronic inflammation in the tumor microenvironment has also been shown to favorize tumor growth and invasiveness and stimulate synthesis of epithelial to mesenchymal transition promoting transcription factors ²⁰. Yet, no inflammation-related genetic or circulating biomarkers have been investigated in detail or established as predictive parameters in the LARC setting so far.

The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammationrelated genetic and hematological parameters in prediction of response after nCRT in patients with
LARC.

113 Methods

114 In silico analysis of published transcriptomics datasets

In silico analysis of published transcriptomics datasets was conducted to identify the best candidate
 genes, whose expression will be measured using quantitative Real Time PCR (qRT-PCR) in
 pretreatment formaline-fixed paraffin-embedded (FFPE) samples.

Gene expression patterns were analyzed using publicly available datasets. By searching the public 118 database the National Center for Biotechnology Information Gene Expression Omnibus (NCBI 119 GEO) using key words rectal cancer, chemoradiotherapy and response to treatment, five adequate 120 sets of data that analyzed pretreatment samples were identified: GSE45404, GSE68204, 121 GSE139255, GSE46862 and GSE3493²¹⁻²⁵. Three datasets were selected where inflammatory 122 response significantly correlated with treatment outcome to nCRT. Gene expression profiles of 123 GSE46862, GSE139255, and GSE45404 570 were obtained from GEO database. The total number 124 of patients of each dataset was 69, 156, and 42 respectively. In all selected studies, the response to 125 treatment was classified according to pathohistological tumor regression grading (TRG) categories 126 127 from the postoperative specimen using Mandard scoring system. Patients were subdivided into responders (TRG 1-2) and non-responders (TRG 3-5). Microarray data were processed and 128 normalized with the Robust Multichip Average method ²⁶. Analysis for statistically significant 129 differences between the two groups was conducted using the standard moderated t-test from the 130 limma package ^{27,28}. Gene set enrichment analysis (GSEA) was performed on selected datasets, and 131 Hallmark, Kyoto encyclopedia of genes and genomes (KEGG), and Reactome gene sets were used 132

- to identify pathway alterations in patients who responded well to the therapy (TRG 1-2) versus those
- 134 who did not (TRG 3-5)^{29,30}.
- 135 Next, the top 100 genes from selected datasets, ranked by the default Signal2Noise metric used in
- 136 previously described GSEA analysis, were extracted and overlapped using Venn diagram software.
- 137 Cytoscape (version 3.10.0) was applied as bioinformatics software to evaluate the potential
- 138 correlation between finally selected genes 31,32 .
- 139 Patient characteristics, treatment and follow-up

In this study 75 patients with LARC treated at the Institute for Oncology and Radiology of Serbia, 140 between June 2020 and January 2022, were prospectively included. The inclusion criteria were 141 142 histopathologically verified adenocarcinoma of the rectum, with a distant margin up to 12 cm from the anal verge by rigid proctoscopy. LARC was defined as T3-T4N0 or any T stage N positive. 143 Pretreatment evaluation included an abdominal and pelvic MRI scan and a computed tomography 144 (CT) scan or X ray of the chest. All patients were treated with long-course nCRT. Radiotherapy 145 (RT) was delivered using volumetric modulated arc therapy-simultaneous integrated boost 146 technique (VMAT-SIB). The dose to mesorectum and pelvic lymph nodes was 45 Gy (1.8 147 Gy/fraction). A SIB was delivered on macroscopic disease region expanded with 2 cm margin with 148 149 a total dose of 54 Gy (2.16 Gy/fraction). Concomitant chemotherapy started on the first day of RT and was administered during the first and the fifth week of RT. The chemotherapy regimen included: 150 151 5-FU (350 mg/m2 on the first day of the first and fifth week of RT) and Leucovorine (25 mg/m2 daily, 5 days of the first and fifth week of RT). 152

Patients were assessed for tumor response in the 8th week after nCRT completion with pelvic MRI 153 154 scan, rigid proctoscopy and digital rectal examination. For patients with cCR and initially distant 155 located tumor no immediate radical surgery was suggested and they were enrolled in a strict followup program ("watch and wait" approach). Patients with cCR where sphincter preservation surgery 156 157 treatment can be delivered, were referred to surgical resection between weeks 8 and 12 from nCRT completion. For patients with partial response (PR), surgery was delayed until week 12-15, 158 159 approximately. The pathohistological response after surgery was assessed according to classification by Mandard. The response to treatment was classified according to pathohistological 160 TRG categories from the postoperative specimen. Responders were defined as patients with cCR 161 without operative treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-162 163 responders were patients classified as TRG 3-5.

Formalin-fixed paraffin-embedded (FFPE) samples taken at the time of disease diagnosis were collected. The project was approved by the Ethics Committee of the Institute for Oncology and Radiology of Serbia (Approval No. 2211-01 from 11.06.2020.) and Ethics Committee of the Faculty of Medicine, University of Belgrade (Approval No. 1322/XII-17 from 03.12.2020.). All patients signed an informed consent.

Before initiation of treatment, ethylenediaminetetraacetic acid (EDTA) peripheral blood was drawn 169 170 by venipuncture and hematological parameters were derived from the absolute differential counts of a complete blood count (CBC). The neutrophil-to-lymphocyte ratio (NLR) was calculated as a 171 ratio of circulating neutrophil and lymphocyte counts, and the platelet-to-lymphocyte ratio (PLR) 172 was defined as the absolute count of platelets divided by the absolute lymphocyte count. The derived 173 neutrophil-to-lymphocyte ratio (dNLR) was calculated as absolute neutrophil count divided by 174 absolute leukocyte minus absolute neutrophil count. The lymphocyte-to-monocyte ratio (LMR), 175 platelet-to-monocyte ratio (PMR), and neutrophil-to-monocyte ratio (NMR) were also analyzed. 176 Patients' pre-treatment hemoglobin levels were obtained. The staging of the tumor was assessed 177 according to the eighth edition of the Union for International Cancer Control (UICC) TNM staging 178 system for rectal cancer ³³. The general condition of the patients was classified using the Eastern 179 cooperative oncology group (ECOG) Scale of Performance Status³⁴. 180

181 RNA isolation and cDNA synthesis

Total RNA was isolated from 2-5 10 μm thick FFPE tissue sections using RNeasy FFPE Kit (Qiagen, Manchester, UK). RNA quality and concentration were determined spectrophotometrically using BioSpec-nano (Shimadzu Scientific Instruments, Kyoto. Japan). The complementary DNA (cDNA) was accessed from 1 μg total RNA using random primers and MultiScribeTM Reverse Transcriptase (50 U/μL) from the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The reaction was performed in 20 μL, using the following program: 25°C for 10 min, 37°C for 120 min, and inactivation at 85°C for 5 min.

189 *Quantitative Real Time PCR (qRT-PCR)*

The mRNA levels of IL6 (RefSeq. NM_000600.5), CXCL9 (RefSeq. NM_002416.3), ID01 190 (RefSeq. NM_002164.6) and CYBB (RefSeq. NM_000397.4) were detected by quantitative real-191 time PCR (qRT-PCR) using oligonucleotides primers (Integrated DNA Technology, Coralville, 192 Iowa, USA) previously designed using NCBI Primer Blast and SybrGreen Gene Expression Master 193 194 Mix (Applied Biosystems), on ABI Prism 7500 Sequence Detection System (Applied Biosystems). The thermal cycling conditions consisted of an UDG activation at 50°C, initial denaturation step at 195 95°C for 2 min followed by 40 cycles of denaturation (15 sec at 95°C) and annealing/extension (1 196 min at 60°C). All experiments were performed in duplicate, including non-template controls in each 197 198 amplification. Gene expression data were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH, RefSeq. NM_002046.5). Data was analyzed using the classical delta-199 200 delta-Ct method, and results expressed in relative units.

201 *Statistical analysis*

For normal distribution data testing, the Kolmogorov-Smirnov and Shapiro-Wilk tests were used.
Descriptive methods (frequencies, percentage, mean, median, standard deviation (SD) and range)

204 were used to summarize the data. The statistical significance level was set at p < 0.05. For comparison

205 of disease and treatment characteristics among different subgroups the Wilcoxon rank sum, Pearson

206 chi-square and Fisher exact tests were used. Also, for evaluating potential predictors of the response, 207 univariate and multivariate logistic regression was used (odds ratio with 95% CI for description, Likelihood Ratio and Wild test), and the responders versus non-responders was set as a dependent 208 variable. We evaluated the sensitivity, specificity, positive predictive value, negative predictive 209 value, and predictive accuracy for clinical assessment of disease presence in comparison with 210 pathohistological response as a gold standard in group of patients where operative treatment was 211 conducted ³⁵. The Receiver Operating Characteristics curve (ROC) methods were applied to 212 investigate the discriminative potential of NLR, PLR, dNLR, LMR, PMR, NMR, initial basophil, 213 eosinophil and monocyte counts, for the good response to treatment (AUC ROC-Area Under the 214 ROC curve according DeLong's method; Likelihood ratio test for AUC ROC; the best cut-off value 215 was set as value with maximum sensitivity and specificity). The statistical analysis was performed 216 217 using the program R (version 3.3.2 (2016-10-31) -- "Sincere Pumpkin Patch"; Copyright (C) 2016 The R Foundation for Statistical Computing; Platform: x86_64-w64-mingw32/× 64 (64-bit); 218 219 downloaded: January 21, 2021). In the search for a measure that outperforms the individual variables, numerical variables that remained significant in the multivariate analysis were utilized to 220 221 create the composite scores. The predictive power of these scores was then tested using the AUC, the Area Under Precision-Recall Curve (AUCRP), the Root Mean Square Error (RMSE) as a metric 222 223 (using the ROCR package) and a random forest classifier (using the randomForest package, with the MeanDecreaseAccuracy metric)³⁶. 224

225 **Results**

After extensive search of the GEO database according to the key words rectal cancer, 226 chemoradiotherapy and response to treatment, three gene expression datasets were finally obtained. 227 Volcano plots were employed to identify genes that exhibited statistically significant differential 228 expression between responders and non-responders, as determined by the adjusted p-value, among 229 selected datasets (Figure 1). Significant alteration defined as those with adjusted p-value lower then 230 231 0.05 was obtained only for GSE 139255 dataset. The results of the differential expression analysis within GSE 139255 are reported in Supplementary Material 1. While KEGG and Reactome GSEA 232 233 analysis yielded no overlap among the selected datasets, the Hallmark analysis exhibited consistent and significant parameters across two datasets. Results of GSEA Hallmark analysis presented in 234 235 Table 1 showed parameters which reached significant levels within GSE46862 and GSE139255 datasets in relation to Hallmark inflammatory response pathway (NOM p-value < 0.05, FDR q-236 237 value < 0.25). Enrichment plots were used to present the expression of genes in selected datasets in Figure 2. 238

239

240





Table 1. GSEA Hallmark analysis in relation to Hallmark inflammatory response pathway.

| Values | | Datasets | |
|--------------------------|--------------|----------|-----------|
| values | GSE45404_570 | GSE46862 | GSE139255 |
| NES ¹ | 1.09 | 1.63 | 1.85 |
| NOM p-value ² | 0.373 | 0.024 | 0.002 |
| FDR q-value ³ | 0.661 | 0.056 | 0.054 |

246 ¹NES - Normalized Enrichment Score; ²NOM p-value – Nominal p-value; ³FDR q-value – False Discovery Rate q-

247 *value;*

242



Figure 2. GSEA enrichment plots for genes included in Hallmark inflammatory response pathway: GSE45404_570 (A); GSE46862 (B); GSE139255 (C).

251 The top 100 genes from each database (Supplementary Material 2) were chosen, and overlapped

among these three datasets using Venn diagram. The results are presented in Figure 3.



Figure 3. Venn diagram showing overlapping of inflammation-related genes between three analyzed datasets.

257 Our focus was on the genes included in the inflammatory response. As a result of overlapping three

- datasets, there were 11 genes present in two of them (PLAU, TGFB2, HGF, IL6, CXCL10, CXCL9,
- 259 IDO1, INHBA, PDGFRB, CYBB, IL24). Statistical significance of these genes among responders
- and non-responders in all three datasets was examined and the results are presented in Table 2.

| | | | | | | Data S | ets | | | | | |
|---------|----------------|----------------|----------------|----------------|---------------|---------------|------------------------------|----------------------|---------------------|----------------|--|--|
| Gene | | GSE45404_570 | | | GSE46862 | | | | GSE139255 | | | |
| | | R | NonR | Test* | R | NonR | Test* | R | NonR | Test* | | |
| N (%) | | 19/42 (45.2%) | 23/42 (54.8%) | - | 28/69 (40.6%) | 41/69 (59.4%) | - | 89/156 (57.1%) | 67/156 (42.9%) | - | | |
| DIAIT | Mean (SD) | 7.6 (0.6) | 7.5 (0.9) | n 0 | 8.1 (0.9) | 7.6 (0.9) | n<0.05 | 1967.0 (2152.2) | 766.5 (637.0) | m <0.01 | | |
| ILAU | Median (Range) | 7.7 (6.2-8.5) | 7.4 (6.0-9.5) | 115 | 8.3 (5.8-9.8) | 7.8 (5.6-9.3) | <i>p</i> <0.03 | 1351.0 (75.0-9876.0) | 604.7 (88.4-3027.0) | <i>p</i> <0.01 | | |
| TGER) | Mean (SD) | 5.0 (0.3) | 5.2 (0.3) | ne | 5.5 (0.7) | 5.1 (0.6) | n < 0.05 | 64.9 (50.9) | 35.9 (25.9) | n < 0.01 | | |
| 101 02 | Median (Range) | 5.1 (4.4-5.7) | 5.1 (4.5-5.7) | 115 | 5.5 (4.3-6.5) | 5.1 (3.7-6.7) | <i>p</i> <0.05 | 51.6 (1.7-261.9) | 30.8 (3.3-114.8) | <i>p</i> <0.01 | | |
| HGF | Mean (SD) | 3.8 (0.3) | 3.8 (0.3) | ne | 5.6 (0.9) | 5.2 (0.8) | ns | 332.6 (371.5) | 166.0 (104.4) | n < 0.01 | | |
| nor | Median (Range) | 3.8 (3.5-4.4) | 3.8 (3.4-4.4) | 115 | 5.6 (4.0-7.6) | 5.0 (3.5-6.7) | 115 | 224.6 (22.2-2733) | 160.0 (30.7-540.1) | <i>p</i> <0.01 | | |
| 11.6 | Mean (SD) | 6.0 (1.3) | 5.6 (1.1) | ns | 5.7 (1.4) | 4.9 (1.1) | <i>n</i> <0.01 | 432.9 (996.6) | 104.3 (200.9) | <i>n</i> <0.01 | | |
| 1120 | Median (Range) | 5.8 (4.0-8.5) | 5.4 (4.2-8.8) | 115 | 5.7 (4.0-9.7) | 4.5 (3.8-8.8) | <i>p</i> <0.01 | 90.7 (1.7-5968.0) | 40.7 (1.1-1207.0) | <i>p</i> <0.01 | | |
| CXCL10 | Mean (SD) | 7.9 (1.4) | 6.7 (1.6) | <i>p</i> <0.05 | 6.4 (1.3) | 5.8 (1.1) | ns | _ | - | NA | | |
| CACLIV | Median (Range) | 7.8 (5.5-10.3) | 6.6 (3.6-10.4) | <i>p</i> <0.05 | 6.2 (4.1-9.5) | 5.6 (4.0-9.5) | 115 | | | 1111 | | |
| CXCL9 | Mean (SD) | 6.8 (1.6) | 5.6 (1.6) | <i>n</i> <0.05 | 5.5 (1.0) | 5.0 (0.8) | <i>p</i> <0.05 | - | - | NA | | |
| UNCL/ | Median (Range) | 6.7 (3.4-9.2) | 5.6 (3.2-9.8) | p coroc | 5.1 (4.3-8.6) | 4.8 (4.1-8.5) | 4.8 (4.1-8.5) <i>p</i> <0.05 | | <i>p</i> <0.02 | | | |
| ID01 | Mean (SD) | 6.5 (1.5) | 5.8 (1.2) | ns | 5.9 (1.0) | 5.4 (1.2) | <i>p</i> <0.05 | - | - | NA | | |
| 1201 | Median (Range) | 6.2 (4.5-10.6) | 5.6 (4.2-8.8) | | 5.7 (3.7-8.2) | 5.2 (3.6-8.5) | Plotte | | | | | |
| INHBA | Mean (SD) | 8.0 (0.8) | 7.9 (1.4) | ns | 6.8 (1.1) | 6.2 (0.9) | ns | 539.0 (768.1) | 240.6 (217.8) | <i>p</i> <0.01 | | |
| | Median (Range) | 7.9 (6.7-9.4) | 8.1 (5.4-10.7) | | 6.6 (5.2-9.2) | 6.4 (4.3-8.3) | | 295.1 (25.2-4582.0) | 172.2 (17.7-1138.0) | P ····· | | |
| PDGFRB | Mean (SD) | 6.9 (0.6) | 6.8 (1.0) | ns | 7.6 (0.8) | 7.1 (0.7) | <i>p</i> <0.01 | 1064.0 (894.3) | 629.1 (614.6) | <i>p</i> <0.01 | | |
| 1201112 | Median (Range) | 6.7 (6.1-8.2) | 6.9 (4.7-8.9) | | 7.5 (6.5-9.2) | 7.1 (5.6-8.7) | P | 781.7 (43.7-3629.0) | 470.9 (59.3-3896.0) | P ····· | | |
| CYBB | Mean (SD) | 5.3 (0.6) | 4.7 (0.5) | <i>p</i> <0.01 | 8.1 (0.9) | 7.5 (1.1) | <i>p</i> <0.01 | - | - | NA | | |
| 0122 | Median (Range) | 5.0 (4.5-6.4) | 4.6 (3.7-5.5) | P | 8.4 (5.5-9.9) | 7.7 (4.6-9.6) | P | | | | | |
| II.24 | Mean (SD) | 5.3 (1.2) | 5.5 (1.4) | ns | 4.8 (0.9) | 4.4 (0.8) | ns | 150.9 (241.4) | 59.7 (66.8) | ns | | |
| 11.47 | Median (Range) | 5.3 (3.3-7.9) | 5.4 (3.4-8.8) | | 4.6 (3.7-7.1) | 4.1 (3.5-7.1) | 115 | 56.5 (1.0-1321.0) | 32.7 (2.2-391.9) | | | |

Table 2. Comparison between responders and non-responders within analyzed datasets in relation to expression of selected genes.

263 ns - not statistically significant; R - responder; NonR - non-responder; *Wilcoxon rank sum test; NA – not available (without data in dataset); PLAU - Plasminogen Activator,

264 Urokinase; TGFB2 - Transforming Growth Factor Beta 2; HGF - hepatocyte growth factor; IL6 - Interleukin-6; CXCL10 - C-X-C Motif Chemokine Ligand 10; CXCL9 - C-X-C Motif

265 Chemokine Ligand 9; IDO1 - Indoleamine 2,3-dioxygenase-1; INHBA - Inhibin Subunit Beta A; PDGFRB - Platelet derived growth factor receptor beta; CYBB - Cytochrome B-245

266 Beta Chain; IL24 - Interleukin 24;

None of the selected genes were found to be statistically significant in all three datasets. In order to validate the potential of gene expression to predict treatment outcome, genes included in the Hallmark inflammatory response pathway (IL6, CXCL9, CYBB) were chosen, along with a gene which had promising potential according to literature search (IDO1)^{37,38}. After the connection among selected genes was checked using Cytoscape network, it was found that three of them (IL6, CXCL9, CYBB) were part of a pathway related to avoiding immune detection.

In order to explore the significance of *in silico* obtained results, the expression of candidate genes 273 was analyzed in the cohort of LARC patients from the Institute for Oncology and Radiology of 274 Serbia. Patients, disease, treatment and outcomes characteristics are presented in Table 3. The 275 majority of patients had T3 stadium and N positive disease. One third of patients were female. All 276 patients completed the planned nCRT. Operative treatment was conducted in 63 patients, and the 277 pathohistological complete response rate was 20.6 % (Table 3). Twelve patients with distally located 278 tumor and complete clinical response were involved in a "watch and wait" approach. One patient 279 had to be excluded from the hematological ratios analysis, because of his chronic lymphocytic 280 281 leukemia and its influence to the parameters of this analysis.

| Characteristics | N (%) | Characteristics | N (%) |
|--|--------------------|--|---------------------------------------|
| Age (years) | | LMR ⁶ | |
| Mean (SD) | 60.8 (10.6) | N (%) | 74/75 (98.7%) |
| Median (Range) | 62.0 (33.0-81.0) | Mean (SD) | 3.5 (1.3) |
| Gender | | Median (Range) | 3.5 (1.3-6.6) |
| Female | 25 (33.3%) | PMR ⁷ | |
| Male | 50 (66.7%) | N (%) | 74/75 (98.7%) |
| Performance status $(PS)^1$ | | Mean (SD) | 555.9 (237.6) |
| ECOG 0 | 52 (69.3%) | Median (Range) | 512.5(231.0-1795) |
| ECOG 1 | 23 (30.7%) | NMR ⁸ | · · · · · |
| T in clinical TNM | | N (%) | 74/75 (98.7%) |
| T2 | 2 (2.7%) | Mean (SD) | 8.8 (5.3) |
| Т3 | 64 (85.3%) | Median (Range) | 7.7 (2.0-46.0) |
| T4 | 9 (12.0%) | Tumor location ⁹ (cm) | |
| N in clinical TNM | | Lower (anal verge ≤ 8) | 60 (80.0%) |
| N0 | 1 (1.3%) | Middle (8 <anal verge<math="">\leq12)</anal> | 15 (20%) |
| N1 | 22 (29.4%) | Tumor morphology | |
| N2 | 52 (69.3%) | Polypoid | 2 (2.6%) |
| UICC ² staging | · · · · | Semi-annular | 17 (22.7%) |
| IIA | 1 (1.3%) | Annular | 56 (74.7%) |
| IIIA | 1 (1.3%) | Extramural vascular invasion | |
| IIIB | 40 (53.4%) | Yes | 25 (33.3%) |
| IIIC | 33 (44.0%) | No | 50 (66.7%) |
| Tumor differentiation | | Stenotic character | |
| well | 39 (52.0%) | Yes | 23 (30.7%) |
| moderate | 30 (40.0%) | No | 52 (69.3%) |
| poor | 6 (8.0%) | IL6 | |
| Mucinous histological type | | N (%) | 57/75 (76.0%) |
| Yes | 13 (17.3) | Mean (SD) | 3.5 (6.6) |
| No | 62 (85.7) | Median (Range) | 0.68 (0.01-36.1) |
| Initial hemoglobin level (g/L) | | CXCL | · · · · · · · · · · · · · · · · · · · |
| Mean (SD) | 130.9 (20.6) | N (%) | 60/75 (80.0%) |
| Median (Range) | 134.4 (79.0-163.8) | Mean (SD) | 1.6 (2.9) |
| Absolute basophil count (10 ⁹ /L) | ```' | Median (Range) | 1.0 (0.1-21.1) |
| Mean (SD) | 0.1 (0.1) | СҮВВ | ```' |
| Median (Range) | 0.0 (0.0-1.0) | N (%) | 59/75 (78.7%) |

| Absolute eosinophil count (10 ⁹ /L) | | Mean (SD) | 2.2 (3.2) |
|--|--------------------|---|-----------------|
| Mean (SD) | 0.2 (0.2) | Median (Range) | 1.0 (0.03-15.7) |
| Median (Range) | 0.2 (0.0-1.0) | ID01 | |
| Absolute monocyte count (10 ⁹ /L) | | N (%) | 57/75 (76.0%) |
| Mean (SD) | 0.6 (0.2) | Mean (SD) | 1.7 (2.3) |
| Median (Range) | 0.5 (0.2-1.4) | Median (Range) | 1.3 (0.2-17.0) |
| NLR ³ | | Operative treatment | |
| N (%) | 74/75 (98.7%) | No (c CR^{10}) | 12 (16.0%) |
| Mean (SD) | 2.9 (2.7) | Yes | 63 (84.0%) |
| Median (Range) | 2.4 (0.9-23.0) | TRG ¹¹ score (operated patients) | |
| PLR^4 | | TRG1 | 13/63 (20.6%) |
| N (%) | 74/75 (98.7%) | TRG2 | 10/63 (15.9%) |
| Mean (SD) | 184.4 (131.6) | TRG3 | 30/63 (47.6%) |
| Median (Range) | 148.9 (66.3-897.5) | TRG4 | 10/63 (15.9%) |
| dNLR ⁵ | | Response to the treatment | |
| N (%) | 74/75 (98.7%) | R^{12} (cCR+TRG1+TRG2) | 35/75 (46.7%) |
| Mean (SD) | 1.9 (1.5) | NonR ¹³ (TRG3+TRG4) | 40/75 (53.3%) |
| Median (Range) | 1.6 (0.1-13.1) | Total | 75 (100%) |

283 ¹ECOG PS - The Eastern Cooperative Oncology Group Performance Status; ²UICC - Union for International Cancer

284 Control; ${}^{3}NLR$ - Neutrophil-to-lymphocyte ratio; ${}^{4}PLR$ - Platelet-to-lymphocyte ratio; ${}^{5}dNLR$ - Derived neutrophil-to-

285 lymphocyte ratio; ⁶LMR - Lymphocyte-monocyte ratio; ⁷PLR - Platelet-lymphocyte ratio; ⁸NMR - Neutrophil-to-

286 monocyte ratio; ⁹Tumor location - distance from anal verge; ¹⁰cCR - Patients without operative treatment due to

287 *complete clinical response;* ${}^{11}TRG$ - Tumor regression grade; ${}^{12}R$ - responders; ${}^{13}NonR$ - non-responders

288 Correlation of clinical evaluation and pathological examination as a gold standard in a group of

patients where operative treatment was conducted is presented in Table 4. Using disease prevalence

of 79.4% the sensitivity, specificity, positive predictive value, negative predictive value and

291 predictive accuracy were calculated (Table 5).

Table 4. Correlation of clinical and pathological CR within a group of patients where

293

operative treatment was conducted.

| | | Pathological assessment of diseasepresence | | | |
|------------|-------|--|-------------|-------------|--|
| Clinical | | Yes | No | Total | |
| assessment | Yes | 46 (73.02%) | 3 (4.76%) | 49 (77.78%) | |
| of disease | No | 4 (6.35%) | 10 (15.87%) | 14 (22.22%) | |
| presence | Total | 50 (79.37%) | 13 (20.63%) | 63 (100%) | |

296 predictive accuracy of clinical evaluation for prediction of disease status using pathological

| ovomination | 96 | • | nold | standard |
|-------------|----|---|------|----------|
| examination | as | а | gola | stanuaru |

| Characteristics | Clinical evaluation |
|------------------------------|----------------------------|
| Sensitivity (95% CI) | 92.0% (80.8-97.8%) |
| Specificity (95% CI) | 76.9% (46.2-95.0%) |
| PPV (95% CI) | 93.9% (85.0-97.6%) |
| NPV (95% CI) | 71.4% (48.2-87.0%) |
| Predictive accuracy (95% CI) | 88.9% (78.4-95.4%) |

297

CI – *confidence interval; NPV* – *negative predictive value; PPV -positive predictive value*

299

Research interest was the comparisons between responders (comprised 35 patients) and non-300 responders (included 40 patients) (Table 6). Initial T and N stadium of disease were not significantly 301 302 different between these two groups. Patients with poorly differentiated tumors and those with mucinous histological type responded to treatment significantly worse than patients with well or 303 moderate tumor differentiation and those without mucinous type (p<0.05 and p<0.01, respectively). 304 According to MRI findings, non-responders presented more often with extramural vascular invasion 305 (EMVI) (p<0.05). Among hematological parameters, significance was found for absolute basophil, 306 307 eosinophil and monocyte counts, dNLR and NMR. In the whole patient group, there was no significant correlation between *in silico* selected genes 308 (IL6, CYBB, CXCL9, IDO1) and response to treatment. On the other hand, when comparison 309 310 between patients where pCR (TRG1) was detected and those who responded the worst (TRG4), statistical significance was found based on IDO1 expression (Wilcoxon rank sum test, p=0.036) 311

312 (Supplementary Table 1).

313Table 6. Comparison of characteristics of responders and non-responders to neoadjuvant314chemoradiotherapy.

| Oberra staristic | The response to treatment | | | | |
|-------------------|---------------------------|------------------|------------------------|--|--|
| Characteristic | Responders | Non-responders | Wilcoxon rank sum test | | |
| Age (years) | | | | | |
| Mean (SD) | 61.5 (10.7) | 60.3 (10.6) | | | |
| Median (Range) | 63.0 (38.0-81.0) | 62.0 (33.0-76.0) | ns | | |
| Gender | | | | | |
| Male | 25 (71.4%) | 25 (62.5%) | | | |
| Female | 10 (28.6%) | 15 (37.5%) | nst | | |
| T in clinical TNM | | | | | |
| T2 | 2 (5.7%) | 0 (0%) | | | |
| Т3 | 29 (82.9%) | 35 (87.5%) | ns [#] | | |
| T4 | 4 (11.4%) | 5 (12.5%) | | | |
| N in clinical TNM | | | | | |
| NO | 1 (2.9%) | 0 (0%) | | | |
| N1 | 13 (37.1%) | 9 (22.5%) | ns# | | |
| N2 | 21 (60.0%) | 31 (77.5%) | | | |
| UICC staging | | | | | |
| IIA+ IIIA+ IIIB | 22 (62.9%) | 20 (50.0%) | ns* | | |

| IIIC | 13 (37.1%) | 20 (50.0%) | |
|--------------------------------|--------------------|--------------------|-----------------|
| Tumor differentiation | | | |
| Well and moderate | 35 (100%) | 34 (85%) | $n < 0.05^{\#}$ |
| Poor | 0 (0%) | 6 (15%) | <i>p</i> <0.05 |
| Mucinous histological type | | | |
| No | 35 (100%) | 27 (67.5%) | $n < 0.01^{\#}$ |
| Yes | 0 (0%) | 13 (32.5%) | p < 0.01 |
| Extramural vascular invasion | | | |
| No | 28 (80%) | 22 (55%) | 0.05* |
| Yes | 7 (20%) | 18 (45%) | <i>p</i> <0.05* |
| Tumor morphology | · · · · | | |
| Polypoid and semi-annular | 14 (40.0%) | 5 (12.5%) | |
| Annular | 21 (60.0%) | 35 (87.5%) | <i>p</i> <0.01* |
| Stenotic character | (******) | | |
| No | 29 (82 9%) | 23 (57 5%) | |
| Ves | 6(17.1%) | 17(42.5%) | p < 0.05* |
| Absolute basonbil count | 0(17.170) | 17 (42.570) | |
| Mean (SD) | 0.03(0.04) | 0.08 (0.16) | |
| Median (Banga) | 0.03(0.04) | 0.08(0.10) | <i>p</i> <0.01 |
| Abaalata aasimarkil aasim | 0.02 (0-0.1) | 0.1 (0-1.0) | |
| Adsolute eosinophii count | 0.17 (0.10) | 0.07 (0.00) | |
| Mean (SD) | 0.17 (0.12) | 0.27(0.22) | p < 0.05 |
| Median (Range) | 0.1 (0-0.53) | 0.2 (0-1.0) | 1 |
| Absolute monocyte count | | | |
| Mean (SD) | 0.52 (0.18) | 0.63 (0.21) | <i>p</i> <0.01 |
| Median (Range) | 0.5 (0.2-1.1) | 0.6 (0.4-1.4) | F |
| Neutrophil-to-lymphocyte ratio | | | |
| Mean (SD) | 3.38 (3.62) | 2.56 (1.5) | ns |
| Median (Range) | 2.5 (1.17-23.0) | 2.27 (0.93-7.46) | 115 |
| Platelet-to-lymphocyte ratio | | | |
| Mean (SD) | 184.8 (141.5) | 184.0 (123.9) | 200 |
| Median (Range) | 144.4 (72.3-897.5) | 150.0 (66.3-681.1) | ns |
| dNLR [§] | | | |
| Mean (SD) | 2.21 (2.02) | 1.61 (0.73) | 0.05 |
| Median (Range) | 1.81 (0.84-13.14) | 1.49 (0.09-3.37) | <i>p</i> <0.05 |
| Neutrophil-to-monocyte ratio | | | |
| Mean (SD) | 10.3 (7.01) | 7.44 (2.48) | |
| Median (Range) | 9.18 (4.56-46.0) | 7.0 (2.0-15.5) | <i>p</i> <0.01 |
| II 6 | | //0 (210 1010) | |
| N (%) | 28/35 (80.0%) | 29/40 (72.5%) | |
| Mean(SD) | 43(86) | 28(40) | ns |
| Median (Bange) | 0.4 (0.01 - 36.1) | 1.4(0.05-16.8) | 115 |
| CVRR | 0.4 (0.01-30.1) | 1.4 (0.05-10.8) | |
| | 20/25 (82.8%) | 20/40 (75.0%) | |
| $M_{con}(SD)$ | 23/33(82.870) | 22(26) | 200 |
| Median (Danas) | 2.1(2.0) | 2.2 (3.0) | ns |
| (Kange) | 1.0 (0.03-10.3) | 1.1 (0.05-15.7) | |
| | 20/25 (02.001) | | |
| N(%) | 29/35 (82.8%) | 31/40 (77.5%) | |
| Mean (SD) | 1.1(0.7) | 2.1 (3.9) | ns |
| Median (Range) | 0.9 (0.3-2.4) | 1.2 (0.1-21.1) | |
| ID01 | | | |
| N (%) | 28/35 (80.0%) | 29/40 (72.5%) | |
| Mean (SD) | 1.5 (1.1) | 1.9 (3.1) | ns |
| Median (Range) | 1.4 (0.2-3.6) | 1.3 (0.2-17.0) | |
| Total | 35 (100%) | 40 (100%) | - |

*Pearson χ^2 Test; #Fisher Exact Test; ns - not statistically significant; $^{\$}dNLR$ -Derived neutrophil-to-lymphocyte ratio

Next, ROC analysis was performed and it revealed the optimal cut-off values for absolute basophil, eosinophil and monocyte counts and NMR, above/below which the possibility of achieving favorable response after nCRT increased significantly (Table 7, Figure 4). The optimal cut-off value, which might distinguish patients with and without good response was not found only for dNLR.

monocyte counts, and relevant events.

```
324
```

| Chamastanistiss | | Absolute count | t | JNI D | NMR |
|---------------------------------------|----------------|----------------|----------------|--------------|----------------|
| Characteristics | Basophil | Eosinophil | Monocyte | anlk | |
| AUC ROC ^a | 68.2% | 66.1% | 67.8% | 62.9% | 68.2% |
| (95% CI) | (56.5-79.9%) | (53.7-78.6%) | (55.5-80.1%) | (50.0-75.8%) | (55.6-80.8%) |
| Likelihood ratio test ^b | <i>p</i> <0.01 | <i>p</i> <0.05 | <i>p</i> <0.05 | ns | <i>p</i> <0.01 |
| ROC-cut-off value ^c | 0.05 | 0.15 | 0.57 | - | 8.12 |
| Sensitivity | 53.8% | 74.4% | 61.5% | | 71.8% |
| (95% CI) | (38.5-69.2%) | (59.0-87.2%) | (46.2-76.9%) | - | (56.4-84.6%) |
| Specificity | 80.0% | 57.1% | 71.4% | | 65.7% |
| (95% CI) | (65.7-91.4%) | (40.0-71.4%) | (57.1-85.7%) | - | (48.6-80.0%) |

325 ^{*a*}Area Under the ROC curve (DeLong's method); ^{*b*}Likelihood ratio test for AUC ROC; ^{*c*}Value with maximum sensitivity

326 and specificity; ns - not statistically significant

327

328

329



Figure 4. ROC curves for the absolute basophil count (A), absolute eosinophil count (B), absolute monocyte count (C) and NMR (D) in relation to response to treatment.

Afterwards, differences between responders and non-responders according to the cut-off values obtained by ROC analysis were examined (Table 8). According to the achieved cut-off values a statistically significant difference in the response was confirmed for the initial basophil, eosinophil and monocyte counts (p < 0.01 for all variables). Initial higher level of these parameters (greater than 0.05, 0.15, 0.57 respectively) were associated with unfavourable responses.

338

```
341
```

prediction the response to nCRT.

| Parameters | Response to nCRT | | | |
|------------------------------|---------------------------|------------|-----------------|--|
| (ROC cut-off value) | responders non-responders | | Pearson χ2 test | |
| Absolute basophil count | | | | |
| ≤ 0.05 | 28 (80.0%) | 18 (45.0%) | 0.01 | |
| > 0.05 | 7 (20.0%) | 22 (55.0%) | <i>p</i> <0.01 | |
| Absolute eosinophil count | | | | |
| ≤ 0.15 | 20 (57.1%) | 10 (25.0%) | <i>p</i> <0.01 | |
| > 0.15 | 15 (42.9%) | 30 (75.0%) | | |
| Absolute monocyte count | | | | |
| ≤ 0.57 | 25 (71.4%) | 15 (37.5%) | <i>p</i> <0.01 | |
| > 0.57 | 10 (28.6%) | 25 (62.5%) | | |
| Neutrophil-to-monocyte ratio | | | | |
| ≤ 8.12 | 12 (34.3%) | 28 (70.0%) | <i>p</i> <0.05 | |
| > 8.12 | 32 (65.7%) | 12 (30.0%) | * | |
| Total | 35 (46.7%) | 40 (53.3%) | - | |

342

Significant variables from the analyses were then used for the construction of a logistic regression 343 model. The UICC staging was included as parameter which unit T and N stadium of disease and has 344 345 high clinical importance. Finally, the model comprised ten variables: UICC staging, tumor differentiation, mucinous histological type, tumor morphology, stenotic character, extramural 346 vascular invasion, as well as NMR, absolute basophil, eosinophil and monocyte counts (Table 9). 347 After univariate analyses were conducted, the extremely high OR values were observed for tumor 348 differentiation and mucinous histological type categories. These values were in correlation with the 349 fact that all patients with mucinous histological type and/or poorly differentiated tumor had achieved 350 bad response. Previously mentioned parameters as well as UICC staging were excluded after 351 univariate analyses. The final model included tumor morphology, NMR, absolute basophil, 352 eosinophil, and monocyte counts. 353

| | Logistic regression | | | | |
|---------------------------------------|-----------------------------|-----------------|-----------------------|--------------------------|--|
| Characteristic | Univariate | | Multivariate | | |
| | Odds Ratio (95%CI) | Wald test | Odds Ratio (95%CI) | Likelihood Ratio test | |
| UICC staging ^{\$} | | | | | |
| IIIC vs. IIA+ IIIA+ IIIB | 1.69 (0.67-4.26) | p=0.265 | - | - | |
| Tumor differentiation | | | | | |
| Poor vs. Well and moderate | 43.8*10 ⁶ (0-∞) | <i>p</i> =0.991 | - | - | |
| Mucinous histological type | | | | | |
| Yes vs. No | 14.99*10 ⁷ (0-∞) | p=0.992 | - | - | |
| Tumor morphology | | | | | |
| Annular vs. Polypoid and semi-annular | 4.67 (1.47-14.82) | <i>p</i> =0.009 | 10.11 (1.81-56.39) | $p^{\#}\!\!=\!\!0.008$ | |
| Stenotic character | | | | | |
| Yes vs. No | 3.57 (1.21-10.52) | p=0.021 | - | <i>p</i> =0.230 | |
| Extramural vascular invasion | | | | | |
| Yes vs. No | 3.27 (1.16-9.23) | p=0.025 | - | p=0.131 | |
| Absolute basophil count | | | | | |
| $> 0.05 \text{ vs.} \le 0.05$ | 4.89 (1.73-13.78) | <i>p</i> =0.003 | 4.55 (1.21-17.13) | $p^{\#}\!\!=\!\!0.025$ | |
| Absolute eosinophil count | | | | | |
| $> 0.15 \text{ vs.} \le 0.15$ | 4.00 (1.50-10.66) | p=0.005 | 3.86 (1.09-13.71) | $p^{\#}\!\!=\!\!0.037$ | |
| Absolute monocyte count | | | | | |
| $> 0.57 \text{ vs.} \le 0.57$ | 4.17 (1.57-11.03) | p=0.004 | 3.46 (1.01-11.89) | $p^{\#}\!\!=\!\!0.049$ | |
| NMR^{ϵ} | | | | | |
| $\leq 8.12 \text{ vs.} > 8.12$ | 4.47 (1.69-11.82) | p=0.003 | 6.38 (1.74-23.39) | $p^{\#}=0.005$ | |

[§]UICC - Union for International Cancer Control; ^eNMR - Neutrophil-to-monocyte ratio; [#]Wild test.

The numerical variables that remained significant in the multivariate analysis were utilized to create eleven different composite scores. These scores were calculated using various combinations of the significant variables (Supplementary Table 2). The best predictive power was observed when the initial eosinophil, basophil, and monocyte counts were combined (Figure 5). The changes in the false negative and true positive rates for the top three composite scores with respect to different cutoff values of these three scores are shown in Figure 6.



Figure 5. Performance of the composite scores with respect to various metrics: AUC - Area 365 Under Curve; AUPRC - Area Under Precision-Recall Curve; RMSE - Root Mean Square 366 Error; RFMDA - Random Forest Mean Decrease in Accuracy; Basoph. - Absolute basophil 367 count; Eosin. - Absolute eosinophil count; Monoc. - Absolute monocyte count; N/M -368 Neutrophil-to-monocyte ratio; Score 1 - Absolute basophil + eosinophil count; Score 2 -369 Absolute basophil + monocyte count; Score 3 - Absolute eosinophil + monocyte count; Score 370 4 - Absolute basophil + eosinophil + monocyte count; Score 5 - Neutrophil-to-monocyte ratio 371 + Absolute monocyte count; Score 6 - Neutrophil-to-monocyte ratio + Absolute eosinophil 372 count; Score 7 - Neutrophil-to-monocyte ratio + Absolute basophil count; Score 8 -373 Neutrophil-to-monocyte ratio + Absolute monocyte + eosinophil count; Score 9 - Neutrophil-374 375 to-monocyte ratio + Absolute monocyte + Absolute basophil count; Score 10 - Neutrophil-tomonocyte ratio + Absolute eosinophil + basophil count; Score 11 - Neutrophil-to-monocyte 376 377 ratio + Absolute monocyte + eosinophil count + basophil count;



400 Discussion

401 The optimal time for assessment of tumor response after nCRT, time for surgery, and how to profile the best candidates for the "watch and wait" approach is still unknown. In this study, we aimed to 402 select patients who would benefit the most from an increase of RT dose and waiting periods longer 403 than 6 weeks after nCRT completion according to initial clinical, pathological, radiological, and 404 hematological parameters, as well as inflammation-related genetic biomarkers chosen by in silico 405 analysis. The identification of these predictive clinical and molecular markers would enable the 406 407 intensification of treatment in selected groups of patients. Better selection of patients with a higher 408 probability of a favorable response to neoadjuvant treatment would contribute to the reduction of morbidity, while improving survival and local control of the disease. On the other hand, patients 409 where a good response to neoadjuvant treatment is not expected would be candidates for other 410 treatment modalities in the initial approach, such as induction polychemotherapy, application of 411 target therapy (e.g. epidermal growth factor receptor inhibitors) or surgery without delay after 412 completion of neoadjuvant treatment. 413

In some cases, pelvic MRI scan performed at 8th week after nCRT completion cannot clearly 414 415 distinguish residual tumor due to post treatment changes and still probably did not achieve the maximum response. The sensitivity of clinical evaluation, according to our results, was 92%. It 416 refers to high probability that disease evaluation will indicate an incomplete response when viable 417 418 tumor cells are present, which is confirmed with pathohystological examination as a gold standard. Therefore, the combination of MRI scan and proctoscopy examination is beneficial when it comes 419 420 to a group of patients who still have residual disease after nCRT, at which point operative treatment is indicated. On the other hand, lower specificity and negative predictive value (NPV) (76.92%, 421 422 71.39%, respectively) suggest that this kind of evaluation is not selective enough for patients who are candidates for the "watch and wait" approach. This method is particularly important in the case 423 424 of distally located rectal cancer when abdominoperineal resection is the only option. In our study, the majority of patients had distant located tumor (80%). The only way to confirm CR after nCRT 425 is strict follow-up with reevaluation every 2-3 months in the first 2 years after treatment completion, 426 followed by continuation of the protocols ³⁹. Evidence suggest that in the case of local regrowth, 427 428 salvage surgery can be done in 95% of patients, which indicate the safety of this approach ¹⁰. However, when near CR is found at the first assessment, the protocols are not well established yet. 429 It is well known that prolongation of period after nCRT completion is associated with higher pCR 430 rate ⁴⁰. In the case when primary response 6-8 weeks after treatment completion is close to cCR, it 431 is beneficial for patients who are not candidates for sphincter preservation surgery to delay surgery 432 with one more clinical assessment after 8-12 weeks in order to achieve the maximum response. 433 434 Simpson at al. reported local regrowth on repeated assessment for 37% of patients whose response was defined as near CR⁴¹. Another article which investigated the role of prolongation of period 435

after nCRT in order to achieve the maximum response, found that 90% of patients with initial near
CR at the first assessment were found to be cCR at the reassessment after 6-12 weeks ⁴². On the
other hand, delaying surgery in order to achieve better response is associated with a higher
probability of distant metastases ⁴³. This fact can be related to local regrowth, but it has not been
proved yet.

441 These circumstances stress the necessity of additional parameters which can guide the selection of patients who can be expected to achieve a complete response. Molecular markers in combination 442 443 with good MRI and rigid proctoscopy examination may allow longer delays in surgery and one more 444 pelvic MRI scan after 8-12 weeks. In this study, we aimed to investigate some genetic factors that were found to be promising candidates using *in silico* methods of previously published datasets. 445 However, statistical significance between responders and non-responders in relation to expression 446 of selected genes (IL6, CYBB, CXCL9, IDO1) was not reached. When comparisons were made in 447 the subgroup of patients who were operated, a significantly higher expression of *IDO1* (p < 0.05) was 448 found for TRG1 compared to TRG4. IDO1 is critical for tryptophan metabolism, and is regarded to 449 have a significant effect on the modulation of T-cell behavior and differentiation of regulatory T-450 cells. In a previous study which explored IDO1 expression using immunohistochemistry in 451 postoperative specimens, the relation to pathological response was not found (p=0.44). The same 452 study showed that higher expression of IDO1 was associated with worse prognosis ³⁸. However, 453 another study exploring nodal-positive LARC revealed that high IDO1 expression in specimens 454 after nCRT completion was associated with improved overall survival (OS)⁴⁴. In our study, all but 455 one patient were nodal-positive and our analyses were conducted on the initial specimens, which 456 457 enabled us to analyze potential predictive biomarkers.

Concerning liquid biopsy parameters, periodic measurement of markers during patient follow up may also be crucial to prove the absence of the disease as well as for early detection of disease progression. This kind of approach has been investigated in metastatic colorectal cancer and it was shown that periodic sampling of liquid biopsy accompanied with ctDNA levels measurements can be valid for monitoring status of the disease and profile the response to treatment ⁴⁵.

The importance of EMVI as a prognostic factor in LARC setting is well established. By comparison 463 of disease-free survival (DFS) between II and III stadium of disease, it was shown that independent 464 from disease stadium, the presence of EMVI results in the worse prognosis ⁴⁶. The predictive role 465 of EMVI has not been defined yet. Sun et al. found that EMVI status was the only factor by 466 multivariate analysis which influences the response to treatment. The focus of this research was the 467 role of initial MRI characteristics on treatment outcome of T3 LARC patients. Patients with ypT0-468 2N0 postoperative category were previously defined as good responders ⁴⁷. In our cohort, 33.3% of 469 patients were EMVI positive, and it was shown that they were more likely to have poor response 470 (p<0.05). Worse response in EMVI positive group of patients can be connected with tumour hypoxia 471

472 and consequent radioresistancy, due to the fact that primary mechanism of radiotherapy 473 effectiveness is formation of reactive oxygen radicals. Hypoxia in solid tumors is a well known problem because of insufficient vascularisation of rapid tumor growth. In order to resolve this in 474 our study, we tried to increase the administrated dose per fraction on the gross disease region (2.16 475 476 Gy/fraction). By doing this, we attempt to cause cell death related to direct DNA damage caused by 477 radiation, and to overcome lower level of oxygen in some parts of the tumor. By combining pCR 478 rate in group of patients where operative treatment was conducted and patients who were enrolled in "watch and wait" program, we achieved 33.3% complete response rate. On the other hand, in 479 EMVI positive group of patients, the complete response was achieved for only 16% of them. The 480 option for this group of patients might be further dose escalation using adaptive MRI-guided 481 radiotherapy which had shown potential for higher cCR rates and wider implementation of organ 482 preservation approaches ⁴⁸. 483

The role of initial basophile count has been previously investigated as a prognostic factor in colorectal cancer. The association between lower basophile level and worse survival as well as aggressive tumor potential has been shown ⁴⁹. To the best of our knowledge, this is the first study to find the predictive role of basophile counts in the rectal cancer settings. Patients with an initial basophile count lower than 0.05 are more likely to achieve good response (p<0.01). Similar results were found in advanced gastric cancer, where worse response to programmed death 1 inhibitor (anti-PD-1 inhibitor) plus chemotherapy was in correlation with a higher level of peripheral basophils ⁵⁰.

491 Comparing literature data on the predictive role of initial eosinophil counts, it has been proposed as 492 a potential predictive marker for immunotherapy in lung cancer, with a higher levels detected in 493 patients with better treatment outcome ⁵¹. It was also found that higher initial level of eosinophil is 494 connected to more effective outcomes when immunotherapy is administrated together with 495 chemotherapy in advanced melanoma ⁵². In our study, a higher initial eosinophil level is associated 496 with worse response, which might be explained by different treatment modalities and the addition 497 of the radiotherapy component.

Analyzing initial monocyte counts, a predictive role was previously reported in the CRC settings, 498 with higher levels detected in patients with poor outcome ⁵³. The same was found in our research 499 where the absolute monocyte levels a higher than 0.57 were related to worse response. The NMR 500 501 has been investigated in low-risk differentiated thyroid carcinoma as a prognostic factor, and it was found that lower initial level is related to a worse prognosis, which is in relation to our findings ⁵⁴. 502 503 Our group has previously shown that hematological parameters easily derived and routinely determined by low-cost and minimally invasive methods might be useful in predicting the response 504 to chemoradiotherapy in patients with anal cancer ⁷. Also, we successfully evaluated the role of 505 hematological parameters in predicting the survival and toxicity to specific treatment in the lung 506 cancer setting 55. 507

508 According to our results, mucinous tumor differentiation was significantly assocciated with poor 509 response (p < 0.01). The study conducted by Simha et al. also found that presence of mucin is associated with larger residual disease and worse prognosis ⁵⁶. Previously it has also been described 510 that mucinous rectal carcinoma is associated with a unique genetic pattern, including more frequent 511 presence of microsatellite instability (MSI), which is caused by a defect in DNA mismatch repair 512 ⁵⁷. The connection of MSI in rectal carcinoma and poorer prognosis has also been reported ⁵⁸. 513 Bearing it in mind, recently presented preliminary results with focus on usefulness of introduction 514 of the anti-PD-1 inhibitor dostarlimab in patients with mismatch repair-deficient (dMMR) LARC 515 patients can be promising to individualise treatment in this group of patients ⁵⁹. 516

This study has some limitations. The sample size is relatively low, but has met the criteria of a minimum number of LARC samples taking into account its incidence and population size in Serbia (95% confidence level)⁶⁰. The evaluation of potential prognostic parameters has not been included, as the enrolled patients are currently under follow-up for long-term outcomes. The predictive model constructed in our study is currently being validated in an independent prospective cohort of patients with LARC treated with nCRT.

523 Conclusions

Based on the logistic regression model, important factors associated with favorable response to nCRT were tumor morphology and hematological parameters which can be easily and routinely derived from initial laboratory results (NMR, eosinophile, basophil and monocyte counts) in a minimally invasive manner. Here, we present evidence that a combined score derived by summing the initial absolute counts of basophils, eosinophils, and monocytes holds the highest predictive value and potential clinical utility. Further studies involving larger cohorts are necessary to validate these initial observations.

Acknowledgements: This study was funded by the Horizon Europe Project STEPUPIORS
(Agreement No. 101079217) and the Ministry of Education and Science of the Republic of Serbia

- 533 (Agreement No. 451-03-47/2023-01/200043).
- 534 **Disclosures:** The authors declare no conflict of interest.

535 Study approval: This study has been approved by the Ethics Committee of the Institute for
536 Oncology and Radiology of Serbia and the Ethics Committee of the Faculty of Medicine, University

of Belgrade, Serbia. All patients signed an informed consent. All experiments have been performed

in accordance with the Helsinki Declaration of 1975, as revised in 2013.

539 Data availability statement: The data that support the findings of this study are available upon 540 reasonable request from the corresponding author. The data are not publicly available due to ethics

restrictions as their containing information could compromise the privacy of patients.

543 **References**

| 544 545 546 | 1. | Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>CA Cancer J Clin</i> . 2021;71(3):209-249. doi:https://doi.org/10.3322/caac.21660 |
|--------------------------|-----|---|
| 547 548 549 | 2. | Nikolic N, Radosavljevic D, Gavrilovic D, et al. Prognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients. <i>Medicina (Kaunas)</i> . 2021;57(10). doi:10.3390/medicina57101108 |
| 550 551 552 | 3. | Cavic M, Krivokuca A, Boljevic I, et al. Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia. <i>J BUON</i> . 2016;21:1287-1295. |
| 553 554 555 | 4. | Brotto K, Malisic E, Cavic M, Krivokuca A, Jankovic R. The Usability of Allele-Specific PCR and Reverse-Hybridization Assays for KRAS Genotyping in Serbian Colorectal Cancer Patients. <i>Dig Dis Sci.</i> 2012;58. doi:10.1007/s10620-012-2469-9 |
| 556 557 558 | 5. | Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. <i>J BUON</i> . 2012;17(3):575-580. http://www.ncbi.nlm.nih.gov/pubmed/23033302 |
| 559 560 561 562 | 6. | Stanojevic A, Samiotaki M, Lygirou V, et al. Data independent acquisition mass spectrometry (DIA-MS) analysis of FFPE rectal cancer samples offers in depth proteomics characterization of response to neoadjuvant chemoradiotherapy. <i>medRxiv</i> . Published online January 1, 2023:2023.05.12.23289671. doi:10.1101/2023.05.12.23289671 |
| 563 564 565 | 7. | Stojanovic-Rundic S, Marinkovic M, Cavic M, et al. The role of haematological parameters in predicting the response to radical chemoradiotherapy in patients with anal squamous cell cancer. <i>Radiol Oncol.</i> 2021;55(4):449-458. doi:10.2478/raon-2021-0039 |
| 566 567 568 | 8. | Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. <i>Ann Surg Oncol.</i> 2012;19(9):2822-2832. doi:10.1245/s10434-011-2209-y |
| 569 570 571 572 | 9. | Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. <i>Lancet Oncol</i> . 2010;11(9):835-844. doi:10.1016/S1470-2045(10)70172-8 |
| 573 574 | 10. | Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant |

575 chemoradiation: a systematic review and meta-analysis. *lancet Gastroenterol Hepatol*.

- 576 2017;2(7):501-513. doi:10.1016/S2468-1253(17)30074-2
- Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete
 clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation:
 impact of salvage therapy on local disease control. *Int J Radiat Oncol Biol Phys.*2014;88(4):822-828. doi:10.1016/j.ijrobp.2013.12.012
- Ferrari L, Fichera A. Neoadjuvant chemoradiation therapy and pathological complete
 response in rectal cancer. *Gastroenterol Rep.* 2015;3(4):277-288.
- 583 doi:10.1093/gastro/gov039
- Maas M, Beets-Tan RGH, Lambregts DMJ, et al. Wait-and-see policy for clinical complete
 responders after chemoradiation for rectal cancer. *J Clin Oncol Off J Am Soc Clin Oncol*.
 2011;29(35):4633-4640. doi:10.1200/JCO.2011.37.7176
- 14. Conde-Muíño R, Cuadros M, Zambudio N, Segura-Jiménez I, Cano C, Palma P. Predictive
 Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer. *Biomed Res Int*.
 2015;2015:921435. doi:10.1155/2015/921435
- 590 15. Li X-F, Jiang Z, Gao Y, Li C-X, Shen B-Z. Combination of three-gene
- immunohistochemical panel and magnetic resonance imaging-detected extramural vascular
 invasion to assess prognosis in non-advanced rectal cancer patients. *World J Gastroenterol*.
 2016;22(38):8576-8583. doi:10.3748/wjg.v22.i38.8576
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a
 meta-analysis. *Gut.* 2001;48(4):526-535. doi:10.1136/gut.48.4.526
- 596 17. Bajpai M, Seril DN, Van Gurp J, et al. Effect of Long-Term Mesalamine Therapy on
 597 Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
 598 *Dig Dis Sci.* 2019;64(3):740-750. doi:10.1007/s10620-018-5378-8
- 599 18. Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. *Nat Rev*600 *Immunol.* 2021;21(10):653-667. doi:10.1038/s41577-021-00534-x
- Long AG, Lundsmith ET, Hamilton KE. Inflammation and Colorectal Cancer. *Curr Colorectal Cancer Rep.* 2017;13(4):341-351. doi:10.1007/s11888-017-0373-6
- 603 20. Vuletić A, Mirjačić Martinović K, Tišma Miletić N, Zoidakis J, Castellvi-Bel S, Čavić M.
- 604 Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and
- Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. *Front cell Dev Biol.*2021;9:750022. doi:10.3389/fcell.2021.750022
- Agostini M, Janssen K-P, Kim I-J, et al. An integrative approach for the identification of
 prognostic and predictive biomarkers in rectal cancer. *Oncotarget*. 2015;6(32):32561-

32574. doi:10.18632/oncotarget.4935

| 610 611 612 | 22. | Millino C, Maretto I, Pacchioni B, et al. Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated With Preoperative Chemoradiotherapy. <i>J Cell Physiol</i> . 2017;232(2):426-435. doi:10.1002/jcp.25441 |
|-------------------|-----|--|
| 613 614 615 | 23. | Park IJ, Yu YS, Mustafa B, et al. A Nine-Gene Signature for Predicting the Response to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer. <i>Cancers (Basel)</i> . 2020;12(4). doi:10.3390/cancers12040800 |
| 616 617 618 | 24. | Gim J, Cho YB, Hong HK, et al. Predicting multi-class responses to preoperative chemoradiotherapy in rectal cancer patients. <i>Radiat Oncol</i> . 2016;11:50. doi:10.1186/s13014-016-0623-9 |
| 619 620 621 | 25. | Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. <i>Cancer Res.</i> 2006;66(7):3370-3374. doi:10.1158/0008-5472.CAN-05-3834 |
| 622 623 624 | 26. | Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. <i>Nucleic Acids Res.</i> 2003;31(4):e15. doi:10.1093/nar/gng015 |
| 625 626 627 | 27. | Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. <i>Stat Appl Genet Mol Biol</i> . 2004;3:Article3. doi:10.2202/1544-6115.1027 |
| 628 629 630 | 28. | Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. <i>Nucleic Acids Res.</i> 2015;43(7):e47. doi:10.1093/nar/gkv007 |
| 631 632 633 | 29. | Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge- based approach for interpreting genome-wide expression profiles. <i>Proc Natl Acad Sci</i> . 2005;102(43):15545-15550. doi:10.1073/pnas.0506580102 |
| 634 635 636 | 30. | Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. <i>Nat Genet</i> . 2003;34(3):267-273. doi:10.1038/ng1180 |
| 637 638 639 | 31. | Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. <i>Genome Res.</i> 2003;13(11):2498-2504. doi:10.1101/gr.1239303 |
| 640 641 | 32. | Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. <i>Bioinformatics</i> . 2011;27(3):431-432. |

- doi:10.1093/bioinformatics/btq675
- 643 33. O'Sullivan B, Brierley J, Byrd D, et al. The TNM classification of malignant tumours-
- towards common understanding and reasonable expectations. *Lancet Oncol.*
- 645 2017;18(7):849-851. doi:10.1016/S1470-2045(17)30438-2
- 646 34. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern
 647 Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5(6):649-655.
- 648 35. MedCalc Software Ltd. Diagnostic test evaluation calculator.
 649 https://www.medcalc.org/calc/diagnostic_test.php
- 650 36. Liaw A, Wiener M. Classification and Regression by RandomForest. *Forest*. 2001;23.
- 37. Chen B, Alvarado DM, Iticovici M, et al. Interferon-Induced IDO1 Mediates Radiation
 Resistance and Is a Therapeutic Target in Colorectal Cancer. *Cancer Immunol Res.*2020;8(4):451-464. doi:10.1158/2326-6066.CIR-19-0282
- Takasu C, Nishi M, Yoshikawa K, et al. Role of IDO expression in patients with locally
 advanced rectal cancer treated with preoperative chemoradiotherapy. *BMC Cancer*.
 2022;22(1):1263. doi:10.1186/s12885-022-10357-1
- Maas M, Lambregts DMJ, Nelemans PJ, et al. Assessment of Clinical Complete Response
 After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and
 MRI: Selection for Organ-Saving Treatment. *Ann Surg Oncol.* 2015;22(12):3873-3880.
 doi:10.1245/s10434-015-4687-9
- 40. Macchia G, Gambacorta MA, Masciocchi C, et al. Time to surgery and pathologic complete
 response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094
 patients. *Clin Transl Radiat Oncol.* 2017;4:8-14. doi:10.1016/j.ctro.2017.04.004
- 41. Simpson G, Hopley P, Wilson J, et al. Long-term outcomes of real world "watch and wait"
 data for rectal cancer after neoadjuvant chemoradiotherapy. *Color Dis Off J Assoc Coloproctology Gt Britain Irel.* 2020;22(11):1568-1576. doi:10.1111/codi.15177
- 42. Hupkens BJP, Maas M, Martens MH, et al. Organ Preservation in Rectal Cancer After
 Chemoradiation: Should We Extend the Observation Period in Patients with a Clinical
 Near-Complete Response? *Ann Surg Oncol.* 2018;25(1):197-203. doi:10.1245/s10434-0176213-8
- 43. van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical
 complete responders after neoadjuvant treatment for rectal cancer in the International
 Watch & Wait Database (IWWD): an international multicentre registry study. *Lancet*
- 674 (London, England). 2018;391(10139):2537-2545. doi:10.1016/S0140-6736(18)31078-X

- 44. Schollbach J, Kircher S, Wiegering A, et al. The local immune phenotype influences 675 676 prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation. Int J Colorectal Dis. 2020;35(2):365-370. doi:10.1007/s00384-019-03466-0 677 van 't Erve I, Medina JE, Leal A, et al. Metastatic colorectal cancer treatment response 678 45. evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells. Clin 679 Cancer Res. Published online December 19, 2022:CCR-22-2538. doi:10.1158/1078-680 0432.CCR-22-2538 681 46. Chand M, Bhangu A, Wotherspoon A, et al. EMVI-positive stage II rectal cancer has 682 similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. 683 Ann Oncol. 2014;25(4):858-863. doi:https://doi.org/10.1093/annonc/mdu029 684 Sun Y, Li J, Shen L, Wang X, Tong T, Gu Y. Predictive value of MRI-detected extramural 685 47. vascular invasion in stage T3 rectal cancer patients before neoadjuvant chemoradiation. 686 Diagn Interv Radiol. 2018;24(3):128-134. doi:10.5152/dir.2018.17286 687 Kensen CM, Betgen A, Wiersema L, et al. Online Adaptive MRI-Guided Radiotherapy for 688 48. Primary Tumor and Lymph Node Boosting in Rectal Cancer. Cancers (Basel). 2023;15(4). 689 doi:10.3390/cancers15041009 690 49. Liu Q, Luo D, Cai S, Li Q, Li X. Circulating basophil count as a prognostic marker of 691 tumor aggressiveness and survival outcomes in colorectal cancer. Clin Transl Med. 692 2020;9(1):6. doi:10.1186/s40169-019-0255-4 693 694 50. Wu C, Qiu Y, Zhang R, et al. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy 695 combination in advanced gastric cancer. J Transl Med. 2022;20(1):386. 696 doi:10.1186/s12967-022-03598-y 697 Caliman E, Fancelli S, Ottanelli C, et al. Absolute eosinophil count predicts clinical 51. 698 outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. 699 Cancer Treat Res Commun. 2022;32:100603. doi:10.1016/j.ctarc.2022.100603 700 Ferrucci PF, Gandini S, Cocorocchio E, et al. Baseline relative eosinophil count as a 701 52. predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget. 702 703 2017;8(45):79809-79815. doi:10.18632/oncotarget.19748 Li Z, Xu Z, Huang Y, et al. The predictive value and the correlation of peripheral absolute 704 53. monocyte count, tumor-associated macrophage and microvessel density in patients with 705 colon cancer. Medicine (Baltimore). 2018;97(21):e10759. 706
- 707 doi:10.1097/MD.00000000010759

- 54. Offi C, Romano RM, Cangiano A, Candela G, Docimo G. Clinical significance of
 neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte
 ratio and prognostic nutritional index in low-risk differentiated thyroid carcinoma. *Acta Otorhinolaryngol Ital organo Uff della Soc Ital di Otorinolaringol e Chir Cerv-facc.*2021;41(1):31-38. doi:10.14639/0392-100X-N1089
- Jokic V, Savic-Vujovic K, Spasic J, et al. Hematological parameters in EGFR-mutated
 advanced NSCLC patients treated with TKIs: predicting survival and toxicity. *Expert Rev Anticancer Ther*. Published online March 2021:1-7. doi:10.1080/14737140.2021.1893694
- 56. Simha V, Kapoor R, Gupta R, Bahl A, Nada R. Mucinous adenocarcinoma of the rectum: a
 poor candidate for neo-adjuvant chemoradiation? *J Gastrointest Oncol*. 2014;5(4):276-279.
 doi:10.3978/j.issn.2078-6891.2014.020
- 57. Mekenkamp LJM, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: poor
 prognosis in metastatic colorectal cancer. *Eur J Cancer*. 2012;48(4):501-509.
 doi:10.1016/j.ejca.2011.12.004
- 58. Hasan S, Renz P, Wegner RE, et al. Microsatellite Instability (MSI) as an Independent
 Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer: A
 National Cancer Database (NCDB) Analysis. *Ann Surg.* 2020;271(4):716-723.
 doi:10.1097/SLA.00000000003051
- 59. Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in Mismatch Repair–Deficient,
 Locally Advanced Rectal Cancer. *N Engl J Med.* 2022;386(25):2363-2376.
 doi:10.1056/NEJMoa2201445
- Flikkema RM, Toledo-Pereyra LH. Sample size determination in medical and surgical
 research. *J Investig Surg Off J Acad Surg Res*. 2012;25(1):3-7.
- 731 doi:10.3109/08941939.2011.648868

- 732 Table and Figure legends
- 733 Table 1. GSEA Hallmark analysis in relation to Hallmark inflammatory response pathway.
- 734 Table 2. Comparison between responders and non-responders within analyzed datasets in
- 735 relation to expression of selected genes.
- 736 Table 3. Patients', disease, treatment and outcomes characteristics.
- Table 4. Correlation of clinical and pathological CR within a group of patients where
 operative treatment was conducted.
- 739 Table 5. Sensitivity, specificity, positive predictive value, negative predictive value and
- 740 predictive accuracy of clinical evaluation for prediction of disease status using pathological
- 741 examination as a gold standard.
- Table 6. Comparison of characteristics of responders and non-responders to neoadjuvant
 chemoradiotherapy.
- Table 7. Results of the ROC analysis for NMR, dNLR, absolute basophil, eosinophil and
 monocyte counts, and relevant events.
- 746 Table 8. The value of NMR, dNLR, absolute basophil, eosinophil and monocyte counts in
- 747 prediction the response to nCRT.
- 748 Table 9. Logistic regression analysis of the response to nCRT.
- 749 Supplementary Material 1. The results of the differential expression analysis within GSE
 750 139255.
- 751 Supplementary Material 2. The top 100 genes from each database.
- 752 Supplementary Table 1. Comparison of genes expression of patients with pCR and those with
- 753 TRG4 postoperative category.
- 754 Supplementary Table 2. Performance of the composite scores with respect to various metrics.
- Figure 1. Volcano plots for selected datasets: GSE45404_570 (A); GSE46862 (B); GSE139255
 (C).
- 757 Figure 2. GSEA enrichment plots for genes included in Hallmark inflammatory response
- 758 pathway: GSE45404_570 (A); GSE46862 (B); GSE139255 (C).

Figure 3. Venn diagram showing overlapping of inflammation-related genes between three
analyzed datasets.

Figure 4. ROC curves for the absolute basophil count (A), absolute eosinophil count (B),
absolute monocyte count (C) and NMR (D) in relation to response to treatment.

Figure 5. Performance of the composite scores with respect to various metrics: AUC - Area 763 764 Under Curve; AUPRC - Area Under Precision-Recall Curve; RMSE - Root Mean Square Error; RFMDA - Random Forest Mean Decrease in Accuracy; Basoph. - Absolute basophil 765 count; Eosin. - Absolute eosinophil count; Monoc. - Absolute monocyte count; N/M -766 767 Neutrophil-to-monocyte ratio; Score 1 - Absolute basophil + eosinophil count; Score 2 -Absolute basophil + monocyte count; Score 3 - Absolute eosinophil + monocyte count; Score 768 4 - Absolute basophil + eosinophil + monocyte count: Score 5 - Neutrophil-to-monocyte ratio 769 + Absolute monocyte count; Score 6 - Neutrophil-to-monocyte ratio + Absolute eosinophil 770 count; Score 7 - Neutrophil-to-monocyte ratio + Absolute basophil count; Score 8 -771 Neutrophil-to-monocyte ratio + Absolute monocyte + eosinophil count; Score 9 - Neutrophil-772 to-monocyte ratio + Absolute monocyte + Absolute basophil count; Score 10 - Neutrophil-to-773 monocyte ratio + Absolute eosinophil + basophil count; Score 11 - Neutrophil-to-monocyte 774 775 ratio + Absolute monocyte + eosinophil count + basophil count;

Figure 6. Relationship between False Negative and True Positive Rates for Top Three
Composite Scores at Different Cut-off Values: Score 2 - Absolute basophil + monocyte count;
Score 3 - Absolute eosinophil + monocyte count; Score 4 - Absolute basophil + eosinophil +
monocyte count;

780

- 781
- 782
- 783
- 784

785

- 787 List of abbreviations:
- 788 CRC colorectal cancer
- 789 LARC locally advanced rectal cancer
- 790 MRI magnetic resonance imaging
- 791 nCRT neoadjuvant chemoradiotherapy
- 792 pCR pathologic complete response
- 793 cCR clinical complete response
- 794 NCBI GEO National center for biotechnology information gene expression omnibus
- 795 TRG tumor regression grading
- 796 GSEA gene set enrichment analysis
- 797 KEGG Kyoto encyclopedia of genes and genomes
- 798 CT computed tomography
- 799 RT radiotherapy
- 800 VMAT-SIB volumetric modulated arc therapy-simultaneous integrated boost technique
- 801 PR partial response
- 802 FFPE formaline-fixed paraffin-embedded
- 803 EDTA ethylenediaminetetraacetic acid
- 804 CBC complete blood count
- 805 NLR neutrophil-to-lymphocyte ratio
- 806 PLR platelet-to-lymphocyte ratio
- 807 dNLR derived neutrophil-to-lymphocyte ratio
- 808 LMR lymphocyte-to-monocyte ratio
- 809 PMR platelet-to-monocyte ratio
- 810 NMR neutrophil-to-monocyte ratio
- 811 UICC Union for International Cancer Control
- 812 ECOG Eastern cooperative oncology group
- 813 cDNA complementary DNA
- 814 qRT-PCR quantitative Real Time PCR

- 815 GAPDH glyceraldehyde-3-phosphate dehydrogenase
- 816 SD standard deviation
- 817 ROC receiver operating characteristics curve
- 818 AUC ROC area under the ROC curve
- 819 AUCRP Area Under Precision-Recall Curve
- 820 RMSE Root Mean Square Error
- 821 EMVI extramural vascular invasion
- 822 RFMDA Random Forest Mean Decrease in Accuracy
- 823 DFS disease-free survival
- 824 anti-PD-1 inhibitor programmed death 1 inhibitor
- 825 MSI microsatellite instability
- 826 dMMR mismatch repair-deficient